TY - JOUR
T1 - Induction of interferon-induced transmembrane protein 3 gene expression by lipopolysaccharide in astrocytes
AU - Nakajima, Akira
AU - Ibi, Daisuke
AU - Nagai, Taku
AU - Yamada, Shinnosuke
AU - Nabeshima, Toshitaka
AU - Yamada, Kiyofumi
N1 - Publisher Copyright:
© 2014 Elsevier B.V.
PY - 2014/12/15
Y1 - 2014/12/15
N2 - Astrocytes are important modulators of the immune and inflammatory reactions in the central nervous system. We have recently demonstrated the role of interferon-induced transmembrane protein 3 (IFITM3) in long-lasting neuronal impairments in mice following neonatal immune challenge by injections of the double-stranded RNA analog polyriboinosinic polyribocytidylic acid. Here, we show that IFITM3 is induced after lipopolysaccharide (LPS) treatment in cultured astrocytes. The induction of IFITM3 by LPS was completely suppressed by the addition of anti-interferon-β (IFN-β) antibody. In addition, neutralization of tumor necrosis factor-α (TNF-α) with its antibody partially inhibited the induction of IFITM3, suggesting that LPS induces IFITM3 through autocrine secretion of IFN-β and TNF-α. Furthermore, experiments using pharmacological inhibitors suggest that LPS induces IFITM3 through activation of TANK-binding kinase 1, p38 mitogen-activated protein kinase, and nuclear factor-κB pathways. Together, these findings may provide new insight into the role of IFITM3 in the pathogenesis of neurodevelopmental diseases associated with immune activation.
AB - Astrocytes are important modulators of the immune and inflammatory reactions in the central nervous system. We have recently demonstrated the role of interferon-induced transmembrane protein 3 (IFITM3) in long-lasting neuronal impairments in mice following neonatal immune challenge by injections of the double-stranded RNA analog polyriboinosinic polyribocytidylic acid. Here, we show that IFITM3 is induced after lipopolysaccharide (LPS) treatment in cultured astrocytes. The induction of IFITM3 by LPS was completely suppressed by the addition of anti-interferon-β (IFN-β) antibody. In addition, neutralization of tumor necrosis factor-α (TNF-α) with its antibody partially inhibited the induction of IFITM3, suggesting that LPS induces IFITM3 through autocrine secretion of IFN-β and TNF-α. Furthermore, experiments using pharmacological inhibitors suggest that LPS induces IFITM3 through activation of TANK-binding kinase 1, p38 mitogen-activated protein kinase, and nuclear factor-κB pathways. Together, these findings may provide new insight into the role of IFITM3 in the pathogenesis of neurodevelopmental diseases associated with immune activation.
UR - http://www.scopus.com/inward/record.url?scp=84918826872&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84918826872&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2014.08.034
DO - 10.1016/j.ejphar.2014.08.034
M3 - Article
AN - SCOPUS:84918826872
SN - 0014-2999
VL - 745
SP - 166
EP - 175
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
ER -